Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Associate Professor
Department of Pathology and Microbiology
University of Nebraska Medical Center
Medical Director
Molecular Diagnostics Laboratory and Human Genetics Laboratory
Department of Pathology and Microbiology
Nebraska Medicine
Omaha, Nebraska
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Scientific Director
Associate Scientific Director
Associate Director, Scientific Services
Senior Director, Educational Strategy
Director, CME Program Development
Associate Director, Educational Strategy
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This educational program is intended for oncologists, pathologists, and other healthcare professionals involved in precision testing and treatment of GI malignancies.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2021, through August 09, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate.
After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.
Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Data on dostarlimab for locally advanced, mismatch repair-deficient rectal cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Expanded results from CheckMate 648 of first-line nivolumab + chemotherapy or ipilimumab vs chemotherapy alone in advanced esophageal squamous cell cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
CAIRO5: FOLFOXIRI + bevacizumab vs FOLFOX/FOLFIRI + bevacizumab in initially unresectable colorectal liver metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.